Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
- PMID: 12499279
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
Abstract
A correlative study was performed to address the impact of epidermal growth factor receptor (EGFR) overexpression on survival and pattern of failure in patients with advanced head and neck squamous cell carcinomas (HNSCCs) enrolled in a Phase III trial and randomized to receive conventional radiotherapy. The study population comprised 155 of 268 (58%) randomized patients with sufficient pretreatment biopsy specimens for immunohistochemical assay. The specimens were dewaxed and incubated after standard preparation with mouse monoclonal antibodies recognizing the extracellular domain of the EGFR molecule. The catalyzed product was visualized with 3,3'-diaminobenzidine Chromogen Kit and lightly counterstained with Mayer's hematoxylin. Quantitative EGFR immunohistochemistry (IHC) was done with SAMBA 4000 Cell Image Analysis System, without knowledge of the clinical outcome, to yield mean absorbance (MOD), staining index (SI), and quick score (QS). These EGFR IHC parameters were correlated with the T stage, N stage, combined stage grouping, and recursive partitioning analysis classes. Subsequently, the EGFR parameters were correlated with the outcome end points, i.e., overall survival (OS), disease-free survival (DFS), local-regional (LR) relapse, and distant metastasis rates. We found that HNSCCs exhibited a wide variation in EGFR expression (MOD, 0.2-66.0; SI, 0.3-97.0; QS, 0.01-69.9) with a relatively strong but nonlinear correlation between MOD and SI (r = 0.79). There was no correlation between EGFR expression and T stage, N stage, stage grouping, and recursive partitioning analysis classes (r = -0.07 to 0.17). The OS and DFS rates of patients with high EGFR-expressing HNSCCs (>median MOD) were highly significantly lower (P = 0.0006 and P = 0.0016, respectively) and the LR relapse rate was highly significantly higher (P = 0.0031) compared with those of patients with low EGFR-expressing HNSCCs. However, there was no difference in the distant metastasis rate between the two groups (P = 0.96). Significant correlations, although somewhat less robust than MOD, were also observed between SI and QS and the OS, DFS, and LR relapse rates. Multivariate analysis showed that EGFR expression was an independent determinant of survival and a robust independent predictor of LR relapse. In summary, this correlative study in a large series of patients revealed that EGFR expression, which varied considerably among HNSCCs, was a strong independent prognostic indicator for OS and DFS and a robust predictor for LR relapse but not for distant metastasis. The data suggest that EGFR IHC should be considered for selecting patients for more aggressive combined therapies or enrollment into trials targeting EGFR signaling pathways.
Similar articles
-
Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.Ear Nose Throat J. 2008 Nov;87(11):634-43. Ear Nose Throat J. 2008. PMID: 19006065 Review.
-
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.Cancer. 2005 Aug 15;104(4):676-81. doi: 10.1002/cncr.21217. Cancer. 2005. PMID: 15981280
-
Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy.Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20. doi: 10.1016/j.ijrobp.2003.10.038. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093894
-
Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.Gynecol Oncol. 2004 Apr;93(1):209-14. doi: 10.1016/j.ygyno.2004.01.006. Gynecol Oncol. 2004. PMID: 15047238
-
The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies.Dan Med Bull. 1998 Apr;45(2):121-34. Dan Med Bull. 1998. PMID: 9587699 Review.
Cited by
-
Rapamycin Induces Phenotypic Alterations in Oral Cancer Cells That May Facilitate Antitumor T Cell Responses.Biomedicines. 2024 May 13;12(5):1078. doi: 10.3390/biomedicines12051078. Biomedicines. 2024. PMID: 38791040 Free PMC article.
-
Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer.Heliyon. 2024 Mar 21;10(6):e28406. doi: 10.1016/j.heliyon.2024.e28406. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38560690 Free PMC article.
-
Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.Mol Biol Rep. 2024 Mar 27;51(1):455. doi: 10.1007/s11033-024-09423-7. Mol Biol Rep. 2024. PMID: 38536540
-
A radiobiological perspective on radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma.Rep Pract Oncol Radiother. 2024 Feb 16;28(6):809-822. doi: 10.5603/rpor.99355. eCollection 2023. Rep Pract Oncol Radiother. 2024. PMID: 38515813 Free PMC article. Review.
-
Expression of EGFR and p16 in Squamous Cell Carcinoma of External Auditory Canal.Kobe J Med Sci. 2024 Jan 31;69(4):E144-E150. doi: 10.24546/0100486232. Kobe J Med Sci. 2024. PMID: 38379276 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous